Status:
COMPLETED
This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.
Lead Sponsor:
Pfizer
Conditions:
Coronary Arteriosclerosis
Eligibility:
All Genders
30-75 years
Phase:
PHASE4
Brief Summary
This study was designed to assess the effects on coronary artery plaque using aggressive lipid-lowering therapy versus moderate lipid-lowering therapy. A substudy will examine the effect of these trea...
Eligibility Criteria
Inclusion
- Angiographic evidence of coronary artery disease as defined by a lesion that has at least 20% reduction in luman diameter by visual (angiographic) estimation in any native coronary artery. LDL cholesterol equal to 125mg/dl - 210mg/dl.
Exclusion
- Patients who are anticipated to undergo coronary bypass surgery or cardiac transplantation during the course of the study. Known major hematologic, neoplastic, metabolic, gastrointestinal or endocrine dysfunction.
Key Trial Info
Start Date :
April 1 1999
Trial Type :
INTERVENTIONAL
End Date :
December 1 2000
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00380939
Start Date
April 1 1999
End Date
December 1 2000
Last Update
December 4 2006
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72205
2
Pfizer Investigational Site
Los Angeles, California, United States, 90048
3
Pfizer Investigational Site
Los Angeles, California, United States, 90095
4
Pfizer Investigational Site
San Diego, California, United States, 92103-8411